Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
KalVista Pharmaceuticals is a biopharmaceutical company focused on developing oral therapies for rare diseases, primarily hereditary angioedema (HAE). Its flagship product, EKTERLY (sebetralstat), is an oral on-demand treatment for HAE attacks, targeting plasma kallikrein. The company advances its pipeline through research, strategic licensing, and global regulatory efforts, competing with established biotech and pharma firms in the rare disease space. It emphasizes innovation, intellectual property, and global commercialization.
This description was generated via AI from an annual report. Updated about 1 year ago.